Das neonatale Immunsystem: Modulation durch regulatorische T-Zellen und CTLA-4 (CD152)

作者：Hebel Katrin; Pierau Mandy; Lingel Holger; Steiner Michael; Krause Hardy; Jorch Gerhard; Brunner Weinzierl Monika C^*

来源：Journal of Laboratory Medicine, 2013, 37(3): 123-129.

DOI：10.1515/labmed-2012-0061

• antibody
• effector T-cell
• immune system
• infants
• lymphocytes
• newborns
• regulatory T-cell.

The dysregulation of CTLA-4 (CD152), a glycoprotein expressed on the surface of lymphocytes, may lead to chronic inflammation. Based on the recent scientific findings, it has become clear that CTLA-4 inhibits the effector function and, thus, shuts down the effector phase of the T-lymphocytes. Interestingly, the CTLA-4-expressing cells become resistant to apoptosis (programmed cell death) and increasingly migrate to the lymph nodes and tissues. Studies have shown that regulatory T cells (Tregs), which switch off unwanted immune responses can inhibit in vivo only if they express an intact CTLA-4 gene. Moreover, it was confirmed that CTLA-4 is not only expressed on the T-lymphocytes but also on the B-lymphocytes. The mice with genetic inactivation of CTLA-4 in the B-lymphocytes show an increased production of the IgM antib odies after immunization. Interestingly, in particular, the B- and T-lymphocytes from the newborns and infants show a strongly increased CTLA-4 expression, suggesting a key immunoregulatory role in the neonatal immune responses. The molecules such as CTLA-4, which regulate the differentiation of the lymphocytes, could provide therapeutic targets during the early childhood to set the course for protection against autoimmunity and allergy.

• 出版日期2013-6